320|0|Public
25|$|Pharmaceuticals—In December 2004, {{the company}} {{announced}} the acquisition of Bayer's plasma products business and renamed it Talecris <b>Biotherapeutics.</b> It purchased Talecris for $83m, and sold the bulk of its shares in October 2009, for {{a net gain of}} $1.8bn.|$|E
25|$|Pfizer's {{research}} and development activities are organised into two principal groups: the PharmaTherapeutics Research & Development Group, which focuses on the discovery of small molecules and related modalities; and the <b>BioTherapeutics</b> Research & Development Group, which focuses on large-molecule research, including vaccines. In 2007, Pfizer invested $8.1billion in {{research and}} development, the largest R investment in the pharmaceutical industry.|$|E
25|$|This {{is common}} with {{companies}} {{that want to}} retain brand recognition while moving away from an outdated image: American Telephone and Telegraph became AT, Kentucky Fried Chicken became KFC to de-emphasize the role of frying {{in the preparation of}} its signature dishes, and British Petroleum became BP. Russia Today has rebranded itself as RT. Genzyme Transgenics Corporation became GTC <b>Biotherapeutics,</b> Inc. in order to reduce perceived corporate risk of sabotage/vandalism by Luddite activists.|$|E
2500|$|In January 2016 Black {{became an}} {{independent}} director of publicly traded biotechnology company Northwest <b>Biotherapeutics</b> (NWBO) {{to investigate the}} market manipulation of the company's stock by the hedge fund [...] "wolfpack". The wolfpack and others use naked shorting of stock to drive promising young biotechs toward bankruptcy or {{to the point where}} they need to raise capital at extremely low valuations from the wolfpack themselves.|$|E
50|$|Live <b>biotherapeutics</b> (probiotics).|$|E
5000|$|Genius <b>Biotherapeutics</b> (Pty) Ltd: {{pharmaceutical}} research and production ...|$|E
5000|$|Prometic <b>Biotherapeutics</b> Inc. (“PBT”), {{based in}} Rockville, MD, USA ...|$|E
50|$|RILS offers {{advanced}} diploma {{programs in}} <b>biotherapeutics</b> and clinical research.|$|E
5000|$|GTC <b>Biotherapeutics</b> - ATryn (recombinant human antithrombin) in goat milk ...|$|E
5000|$|John S. Burg - Head of Biochemistry, Ab Initio <b>Biotherapeutics.</b>|$|E
5000|$|... 1968: Millipore {{introduces}} its Pellicon cassette product, for purifying <b>biotherapeutics.</b>|$|E
5000|$|<b>Biotherapeutics</b> for Cancer Treatment - BioCanRx (2014-2019) - Ottawa Hospital Research Institute, Ottawa, Ontario, ...|$|E
50|$|In 2009, CSL Limited {{attempted}} to takeover Talecris <b>Biotherapeutics</b> (the former plasma business of Bayer HealthCare LLC, Biological Products Division) for $3,1 billion but {{was stopped by}} the Federal Trade Commission. On June 1, 2011, a year after announcing the $4 billion deal, Grifols completed a takeover of Talecris <b>Biotherapeutics,</b> headquartered in Research Triangle Park in North Carolina, with over 2000 employees.|$|E
5000|$|Asterias <b>Biotherapeutics,</b> {{which is}} re-initiating Geron's stem cell trial for {{spinal cord injury}} using the stem cell assets {{acquired}} from Geron in 2013. The CEO of this subsidiary is Pedro Lichtinger, former CEO of Optimer Pharmaceuticals, which along with Trius Therapeutics was acquired by Cubist Pharmaceuticals for $1.6 billion in July 2013. Asterias <b>Biotherapeutics</b> stock is traded on the New York Stock Exchange market exchange (...) [...]|$|E
5000|$|Li, A. P. (2012) Editorial: {{metabolism}} and drug-drug interaction potential of <b>biotherapeutics.</b> Current Drug Metabolism 13, 881.|$|E
5000|$|Taliglucerase alfa {{is made by}} the Israeli <b>biotherapeutics</b> company Protalix {{and sold}} by the American {{pharmaceutical}} company Pfizer ...|$|E
5000|$|Genedata Expressionist - For the analysis, {{management}} and reporting of metabolomics, proteomics, and <b>biotherapeutics</b> characterization studies based on mass spectrometry.|$|E
50|$|The company {{acquired}} Healthpoint <b>Biotherapeutics,</b> {{a specialist}} in the bioactives area of advanced wound management, for $782 million in December 2012.|$|E
50|$|He is current Executive Vice President Research & Development for Synthetic Biologics {{and sits}} on the Scientific Advisory Board of Agilis <b>Biotherapeutics,</b> LLC.|$|E
50|$|Affimer {{technology}} has been commercialised and developed by Avacta, who are developing these affinity reagents as tools for research and diagnostics and as <b>biotherapeutics.</b>|$|E
50|$|Autologous patient-specific {{tumor antigen}} {{response}} (apSTAR) {{technology is a}} new cancer treatment procedure being developed by IMULAN <b>BioTherapeutics,</b> LLC and Veterinary Cancer Therapeutics, LLC for comparative oncology.|$|E
50|$|Protalix <b>BioTherapeutics</b> is an Israeli {{pharmaceutical}} company whose plant-based enzyme, taliglucerase alfa, {{has been approved}} by the U.S. Food and Drug Administration for the treatment of Gaucher disease.|$|E
50|$|Stealth Peptides, {{a privately}} held company, {{was founded in}} 2006 to develop {{intellectual}} property licensed from several universities including elamipretide; it subsequently {{changed its name to}} Stealth <b>BioTherapeutics.</b>|$|E
50|$|In 1990, Mazumdar {{incorporated}} Biocon Biopharmaceuticals Private Limited (BBLP) {{to manufacture}} and market a select range of <b>biotherapeutics</b> {{in a joint}} venture with the Cuban Center of Molecular Immunology.|$|E
50|$|Veterinary Cancer Therapeutics, LLC, a {{subsidiary}} of IMULAN <b>BioTherapeutics,</b> LLC, is in exploratory trials for canine osteosarcoma, canine melanoma, canine and feline fibrosarcoma, and several other forms of cancer.|$|E
50|$|Celacade is a non-pharmacological {{treatment}} {{also known}} as Immune Modulation Therapy (IMT), developed by the Canadian-based <b>biotherapeutics</b> company Vasogen, for treatment of chronic heart failure and peripheral artery disease.|$|E
50|$|Northwest <b>Biotherapeutics</b> is a development-stage American {{pharmaceutical}} company headquartered in Maryland {{that focuses on}} developing immunotherapies against different types of cancer. The company was founded in 1996 by Alton L. Boynton.|$|E
50|$|Ciechanover {{has served}} on the Scientific Advisory Boards of the {{following}} companies: Rosetta Genomics (Chairman), BioLineRx, Ltd, StemRad, Ltd, Allosterix Ltd, Proteologics, Inc, MultiGene Vascular Systems, Ltd, Protalix <b>BioTherapeutics</b> and BioTheryX, Inc.|$|E
50|$|In 2007 Isis and Alnylam Pharmaceuticals, {{which focuses}} on RNA interference, partnered to form a 50/50 joint venture, Regulus Therapeutics, to apply their {{intellectual}} property and know-how around oligomer <b>biotherapeutics</b> to micro-RNA targets.|$|E
50|$|A review {{published}} by Muller and Milton in Nature Reviews Drug Discovery critically discusses the {{various aspects of}} TI determination and interpretation in a translational drug development setting for both small molecules and <b>biotherapeutics.</b>|$|E
5000|$|Pichia pastoris {{was used}} for the {{production}} of over 500 <b>biotherapeutics</b> like interferon gamma.However, one drawback of this protein expression system is the over-glycosylation with high mannose structure which potentially is the cause of immunogenicity.|$|E
5000|$|Grifols, S.A., {{a global}} health care company {{in one of}} the most intense {{antitrust}} investigations in recent FTC history, resulting in the approval of its $4 billion acquisition of Talecris <b>Biotherapeutics</b> Holdings Corp., creating the world's third-largest plasma-products manufacturer ...|$|E
5000|$|Pharmaceuticals—In December 2004, {{the company}} {{announced}} the acquisition of Bayer's plasma products business and renamed it Talecris <b>Biotherapeutics.</b> It purchased Talecris for $83m, and sold the bulk of its shares in October 2009, for {{a net gain of}} $1.8bn.|$|E
50|$|In 2011, a lab team member, Liat Benmoyal-Segal, {{published}} a paper together with Soreq indicating {{the relevance of}} {{a variant of the}} acetylcholinesterase protein in the treatment of Parkinson's. Protalix <b>BioTherapeutics</b> developed the variant, PRX-105, and began phase I clinical trials.|$|E
5000|$|... 2002 - MU's Randall Prather {{along with}} Immerge <b>BioTherapeutics,</b> clones the first {{miniature}} swine {{with a specific}} gene that causes human rejection “knocked out” of their DNA. The feat takes scientists {{a step closer to}} the possibility of pig-to-human organ transplantation ...|$|E
50|$|In November 2016 Dipp and Longwood {{helped launch}} Axial <b>Biotherapeutics,</b> which aimed to {{modulate}} the gut-brain axis to treat neurological diseases; its strategy at launch was open with company considering developing drugs {{to influence the}} gut microbiota as well as probiotics; Dipp took a board seat.|$|E
